Financial Performance - The company achieved a revenue of RMB 12,063.86 million in 2021, representing a year-on-year growth of 14.67%[8] - The net profit attributable to shareholders was RMB 1,775.68 million, an increase of 3.54% compared to the previous year[8] - The main business net profit, excluding non-recurring gains and losses, was RMB 1,627.05 million, reflecting a growth of 13.66% year-on-year[8] - The total operating revenue for the year was RMB 12,063.86 million, representing a year-on-year increase of 14.67%[17] - The net profit attributable to shareholders was RMB 1,775.68 million, with a decrease of 9.79% compared to the previous year[17] - The cash flow from operating activities was RMB 1,431.55 million, reflecting a decline of 11.96% year-on-year[17] - The basic earnings per share for the year was RMB 1.90, showing a 3.83% increase from the previous year[18] - The company's total revenue for 2021 reached RMB 12,063.86 million, a year-on-year increase of 14.67% from RMB 10,520.41 million in 2020[50] - Net profit attributable to shareholders for 2021 was RMB 1,775.68 million, reflecting a 3.54% increase compared to RMB 1,714.91 million in the previous year[50] Research and Development - The company has made significant progress in R&D, with the injection of Triptorelin microspheres completing Phase III clinical trials and registration application[10] - The V-01 vaccine, developed in collaboration with the Chinese Academy of Sciences, has shown excellent safety and immunogenicity in Phase I/II trials and is currently undergoing Phase III trials globally[11] - The company is investing RMB 500 million in R&D for new drug development, focusing on oncology and autoimmune diseases[29] - Research and development expenses for the reporting period amounted to approximately RMB 1,523.26 million, an increase of 53.93% year-on-year, accounting for 12.63% of the total operating revenue[45] - The company is focusing on high-barrier complex formulations and innovative drugs, particularly in reproductive assistance, digestive, and oncology fields[45] - The company has 932 research and development personnel as of the end of the reporting period, reflecting a strong commitment to innovation[45] - The company has initiated Phase III clinical trials for a recombinant COVID-19 vaccine in multiple countries, showcasing its commitment to addressing urgent health needs[45] Market Strategy and Expansion - The company plans to accelerate new product development and enhance operational efficiency through digital and intelligent transformation[15] - The company aims to achieve carbon neutrality by 2055 and will increase investment in environmental protection and energy conservation[16] - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[29] - The company will continue to focus on unmet clinical needs and internationalization efforts to enhance market share[15] - The company is actively seeking international collaboration opportunities and has established a carbon neutrality goal by 2055, incorporating ESG criteria into management assessments[12] - The company is enhancing its product structure by focusing on innovative drugs and high-barrier complex formulations[67] Product Development and Portfolio - The sales revenue from chemical preparations amounted to RMB 7,224.42 million, representing a 33.71% year-on-year growth and accounting for 60.56% of the company's main business revenue[51] - The company has established a comprehensive product cluster covering various therapeutic areas, indicating a diversified product portfolio[44] - The company has developed diagnostic kits for HIV and COVID-19, enhancing its product portfolio[33] - The company has launched two new products in the last quarter, contributing to a 10% increase in sales volume[29] - The company has completed Phase III clinical studies for the injectable Triptorelin microspheres and is progressing with other complex formulations[51] Financial Management and Investments - The company has committed RMB 19.45 million to public welfare donations during the reporting period[16] - The company reported a significant increase in energy costs, which accounted for 6.94% of total operating costs, compared to 7.49% in the previous year[79] - The company has not utilized all the raised funds from its non-public stock issuance as of June 15, 2021[35] - The company has a profit distribution plan to distribute a cash dividend of RMB 13.00 per 10 shares to shareholders[21] - The company has established a strong R&D capability with international standards, focusing on areas such as reproductive assistance, digestion, and oncology[66] Corporate Governance and Compliance - The company has engaged Minsheng Securities as its sponsor for continuous supervision from September 20, 2016, to December 31, 2021[35] - The company has appointed new representatives for continuous supervision due to personnel changes at Minsheng Securities[35] - The company’s financial advisor role is not applicable for the current year[36] - The company’s contact information includes a dedicated board secretary and securities representative for investor relations[30] - The company’s annual report is disclosed on multiple platforms including the Shenzhen Stock Exchange and Hong Kong Stock Exchange[30] Sustainability and ESG Initiatives - The company is actively seeking international collaboration opportunities and has established a carbon neutrality goal by 2055, incorporating ESG criteria into management assessments[12] - The company has introduced ESG assessment indicators into management evaluations to enhance sustainable development efforts[63] - The company is committed to improving its quality management system, ensuring product safety and stability across all business processes[69] Challenges and Risks - The company has reported a significant market risk associated with commodity price fluctuations, necessitating the use of financial derivatives for risk management[156] - The company has faced significant changes in project feasibility due to regulatory adjustments and cost control measures affecting the sales of the "Lijun Group's Limin Hair Injection" project[169] - The company has suspended the development of certain products due to market changes, reallocating funds to enhance capital efficiency[180]

70 丽瑞医药 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (在中華人民共和國註冊成立的股份有限公司) 股份代號：1513 DECIENTER 電 STERFILE LE Hallene II 2021 中期報告 * 僅供識別 目錄 財務摘要 3 第六節 環境和社會責任 104 第一節 重要提示和釋義 5 第七節 股份變動及股東情況 123 第二節 公司簡介和主要財務指標 10 第八節 優先股相關情況 134 第三節 管理層討論與分析 14 第九節 債券相關情況 135 第四節 公司治理 72 第五節 重要事項 77 麗珠醫藥集團股份有限公司 二零二一年中期報告 1 第十節 財務報告 136 備查文件目錄 （一） 載有法定代表人簽名的本公司2021年半年度報告文本。 （二） 載有公司負責人、主管會計工作負責人、會計機構負責人（會計主管人員）簽名並蓋章的按照《中國 企業會計準則》編製，本公司截至2021年6月30日止六個月的未經審計的財務報告。 （三） 本報告期內在中國證監會指定網站上公開披露過的所有本公司文件的正本及公告的原稿。 （四） 在香港交易及結算所有限 ...